Overview

Ocular Micro-vascular Research Base on Functional Slip Lamp Biomicroscopy

Status:
Unknown status
Trial end date:
2020-06-30
Target enrollment:
0
Participant gender:
All
Summary
Dry eye disease (DED), as one of the most common ocular surface diseases that affecting visual acuity, is highly associated with ocular surface inflammation. Until now, there is no accurate quantization index system to evaluate real-time ocular surface inflammation. Besides, an individualized therapy for ocular surface inflammation is also badly needed. As we all know, conjunctival congestion is one of the important clinical appearance of ocular surface inflammation. Hence, we suggest that several specific microvascular indexes could measure the change of ocular surface inflammation. Our program is aiming to investigate the correlation between inflammatory factors and blood flow velocity as well as microvascular distribution detecting from bulbar conjunctiva through our own devices and software.Futhermore, we tend to compare ocular surface microvascular indexes and microvascular distribution in normal people and dry eye patients in order to establish a database for Chinese people. By confirming the relationship between ocular surface microvascular indexes and ocular inflammation, we hope to set up new diagnostic criteria for ocular inflammation and an individualized therapeutic regimen based on ocular surface microvascular indexes. Finally, we want to establish a precision diagnostic and therapeutic pattern for dry eye disease.
Phase:
Phase 4
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Zhongshan Ophthalmic Center, Sun Yat-sen University
Treatments:
Anti-Inflammatory Agents
Fluorometholone
Tacrolimus
Criteria
Inclusion Criteria:

- age ≧ 18 years

- Ocular Surface Disease Index (OSDI) ≧ 12.

- A 5-min Schirmer I test (ST) result showing less than 5 mm of moisture on the strip.

- A noninvasive average tear-film break-up time (NI-avBUT) less than 5 s.

Exclusion Criteria:

- Patients were excluded if they had an eye infection, injury, non-DE ocular
inflammation, ocular surgery within the last 6 months, or any concurrent treatment
that might interfere with the interpretation of the study results (systemic
corticosteroids, immunosuppressive therapy, or hormonal replacement therapy). Patients
were also excluded if they had an uncontrolled disease, had a significant illness or
were pregnant or lactating.